Iron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of Pregnancy

ConditionPregnancy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-35
SponsorETH Zurich

About this trial

This study evaluates iron absorption from three antenatal supplements, 30 mg MMS, 60 mg MMS, and 60 mg IFA, in 50 pregnant Kenyan women in their second trimester. Using a randomized crossover design and stable iron isotopes, we will compare bioavailability in both fasted and fed states. Additionally, the trial will investigate if daily dosing triggers a hepcidin response that inhibits subsequent absorption, testing whether alternate-day dosing is a more effective strategy for treating iron deficiency.

Eligibility criteria

Qualifiers

female

pregnant at gestational age 12 (±1) weeks (dated by ultrasound)

age 18 to 35 y

Hb concentration ≥80 g/L

Disqualifiers

severe anemia (defined as Hb <80 g/L)

malaria

sickle cell disease (SS and SC)

hemoglobin C disease (CC).

Trial design

Treatments tested in this trial

  • MMS with 30 mg iron
  • MMS with 60 mg iron
  • IFA with 60 mg iron

Treatment groups

50 Participants
are divided into 2 treatment groups

Sponsors and collaborators